Vaia Florou

1.5k total citations · 1 hit paper
56 papers, 822 citations indexed

About

Vaia Florou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vaia Florou has authored 56 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 19 papers in Cancer Research. Recurrent topics in Vaia Florou's work include Cancer Genomics and Diagnostics (16 papers), Sarcoma Diagnosis and Treatment (14 papers) and Pancreatic and Hepatic Oncology Research (13 papers). Vaia Florou is often cited by papers focused on Cancer Genomics and Diagnostics (16 papers), Sarcoma Diagnosis and Treatment (14 papers) and Pancreatic and Hepatic Oncology Research (13 papers). Vaia Florou collaborates with scholars based in United States, Austria and Spain. Vaia Florou's co-authors include Breelyn A. Wilky, Jonathan C. Trent, Despina S. Kolonias, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Ignacio Garrido‐Laguna, Wungki Park, Darcy A. Kerr and Ty K. Subhawong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Vaia Florou

50 papers receiving 820 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

2019 260 citations Breelyn A. Wilky, Vaia Florou et al. profile →

Peers

Countries citing papers authored by Vaia Florou

Since Specialization

Citations

This map shows the geographic impact of Vaia Florou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vaia Florou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vaia Florou more than expected).

Fields of papers citing papers by Vaia Florou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vaia Florou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vaia Florou. The network helps show where Vaia Florou may publish in the future.

Co-authorship network of co-authors of Vaia Florou

This figure shows the co-authorship network connecting the top 25 collaborators of Vaia Florou. A scholar is included among the top collaborators of Vaia Florou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vaia Florou. Vaia Florou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma 2025 ·JAMA Network Open ·(unknown), Matthew Shaw, (unknown), (unknown), Heloisa P. Soares, Chris Nevala-Plagemann, Ignacio Garrido‐Laguna, Vaia Florou	8
2	Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma 2025 ·Clinical Cancer Research ·(unknown), Roman Groisberg, Andrew Elliott, Don S. Dizon, Andreas Seeber, Geoffrey T. Gibney, Margaret von Mehren, Kenneth Cardona, Michael J. Demeure, Richard F. Riedel, Vaia Florou, Alexander J. Chou, Jaime F. Modiano, Abhijeet Kumar, Moh’d Khushman, Gina Z. D’Amato, Andrea P. Espejo Freire, (unknown), Jonathan C. Trent	0
3	Gemcitabine-induced myositis in a patient with pancreatic cancer 2025 ·BMJ Case Reports ·(unknown), Chris Nevala-Plagemann, Vaia Florou, Ignacio Garrido‐Laguna	1
4	A Review of Genomic Testing and SDH‐ Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST 2025 ·Cancer Medicine ·Vaia Florou, Michelle F. Jacobs, Ruth Casey, (unknown), Brian Owens, Margarita Raygada, (unknown), Samantha Greenberg	0
5	A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. 2024 ·Journal of Clinical Oncology ·Thatcher Heumann, Mark Yarchoan, (unknown), Jiayun Lu, Daneng Li, Paul R. Kunk, Renuka Iyer, Farshid Dayyani, Lionel Aurelien Kankeu Fonkoua, (unknown), Olumide B. Gbolahan, Milind Javle, S. Lindsey Davis, Vaia Florou, James R. Wright, Elad Sharon, Hao Wang, Gregory B. Lesinski, Nilofer S. Azad	3
6	Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets 2024 ·JCO Precision Oncology ·Erik B. Faber, (unknown), (unknown), (unknown), Peter J. Hosein, Anthony F. Shields, Heinz‐Josef Lenz, (unknown), Sanjay Goel, Matthew J. Oberley, Giuseppe Malleo, Claudio Luchini, Justin H. Hwang, Vaia Florou, Ignacio Garrido‐Laguna, Emil Lou	3
7	A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer 2024 ·Investigational New Drugs ·Patrick M. Boland, Heinz‐Josef Lenz, Kristen K. Ciombor, Vaia Florou, Michael J. Pishvaian, Mike Cusnir, Deirdre Jill Cohen, Jessie Yanxiang Guo, Min Tang, Prabhu Rajagopalan, Sandra E. Wiley, Richard Ghalie, (unknown)	2
8	Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers 2024 ·JCO Precision Oncology ·Thejus Jayakrishnan, Yasmine Baca, Joanne Xiu, M. Patel, Benjamin A. Weinberg, Emil Lou, Jashodeep Datta, Moh’d Khushman, Pat Gulhati, Sanjay Goel, Tiago Biachi De Castria, Vaia Florou, (unknown), Suneel Kamath, Alok A. Khorana	3
9	689TiP A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors 2024 ·Annals of Oncology ·Vaia Florou, (unknown), A. Morton, (unknown), (unknown), Yun Sun, Xingming Tang, Simin Liu, (unknown)	1
10	Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC 2023 ·Clinical Cancer Research ·Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa E. Affolter, Heloisa P. Soares, Chris Nevala-Plagemann, Courtney L. Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido‐Laguna	10
11	Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden 2023 ·Journal for ImmunoTherapy of Cancer ·Vaia Florou, Charalampos S. Floudas, Asaf Maoz, Abdul Rafeh Naqash, (unknown), Aik Choon Tan, Ethan Sokol, Garrett M. Frampton, Heloisa P. Soares, Sonam Puri, Umang Swami, Breelyn A. Wilky, Peter J. Hosein, Jonathan C. Trent, Gilberto Lopes, Wungki Park, Ignacio Garrido‐Laguna	9
12	Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report 2023 ·Journal of Gastrointestinal Oncology ·(unknown), (unknown), Vaia Florou, Chris Nevala-Plagemann, Ignacio Garrido‐Laguna	1
13	Discrepancies between tumor genomic profiling and germline genetic testing 2022 ·ESMO Open ·(unknown), (unknown), Samantha Greenberg, Wendy Kohlmann, Joanne Jeter, Sarah V. Colonna, Theresa L. Werner, Conan G. Kinsey, Glynn Weldon Gilcrease, John R. Weis, Jonathan Whisenant, Vaia Florou, Ignacio Garrido‐Laguna	10
14	Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer 2022 ·Current Oncology Reports ·Vaia Florou, Ignacio Garrido‐Laguna	20
15	Emerging mechanisms of immunotherapy resistance in sarcomas 2022 ·Cancer Drug Resistance ·Vaia Florou, Breelyn A. Wilky	5
16	Current Management of Angiosarcoma: Recent Advances and Lessons From the Past 2021 ·Current Treatment Options in Oncology ·Vaia Florou, Breelyn A. Wilky	28
17	Biomarkers of therapeutic response with immune checkpoint inhibitors 2021 ·Annals of Translational Medicine ·(unknown), Jhanelle E. Gray, Theresa A. Boyle, Vaia Florou, Sonam Puri	3
18	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction 2021 ·Annals of Translational Medicine ·Vaia Florou, Sonam Puri, Ignacio Garrido‐Laguna, Breelyn A. Wilky	11
19	Intravenous Leiomyomatosis: A Rare Diagnosis With Aggressive Potential 2020 ·JCO Oncology Practice ·Vaia Florou, Elke A. Jarboe, Georgios Deftereos	3
20	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution 2019 ·Journal for ImmunoTherapy of Cancer ·Vaia Florou, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Despina S. Kolonias, Mohamed Uduman, John C. Castle, Jennifer S. Buell, Jonathan C. Trent, Breelyn A. Wilky	135

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact